Propanc Biopharma’s CEO to Attend 43rd Meeting of the European Organization of Research & Treatment of Cancer (EORTC), Dec 15 - 17 Oct 12, 2022
Propanc Biopharma Targets Pancreatic & Ovarian Cancers for PRP Clinical Studies with Combined Markets to Reach Over $14.3 Billion by 2027 Sep 29, 2022
Propanc Biopharma Synthesizes Recombinant Trypsinogen & Chymotrypsinogen Via POP1 Joint Research & Drug Discovery Program Aug 23, 2022
Propanc Biopharma Receives Notice of Allowance for Proenzyme Compositions to Treat Cancer from the European Patent Office Aug 16, 2022
Propanc Biopharma Establishes Joint Research Collaboration Agreement with the Universities of Jaén and Granada Aug 3, 2022
Propanc Biopharma’s CSO Reflects on Unique Anti-Cancer Effects of PRP Discovered Over Past Decade Jul 28, 2022
Propanc Biopharma Successfully Produces Synthetic Recombinant Trypsinogen Via POP1 Joint Research & Drug Discovery Program Jul 19, 2022
Propanc Biopharma’s CEO Believes Lead Asset Could Unlock Value as PRP Advances to Phase I, First-In-Human Study in Advanced Cancer Patients Jul 12, 2022
